{"id":9876,"date":"2025-03-27T19:11:16","date_gmt":"2025-03-27T19:11:16","guid":{"rendered":"https:\/\/www.lupuscanada.org\/?p=9876"},"modified":"2025-10-24T16:01:26","modified_gmt":"2025-10-24T16:01:26","slug":"anifrolumab-plus-standard-care-reduit-les-lesions-organiques-chez-les-patients-atteints-de-led-resultats-de-letude","status":"publish","type":"post","link":"https:\/\/www.lupuscanada.org\/fr\/anifrolumab-plus-standard-care-reduit-les-lesions-organiques-chez-les-patients-atteints-de-led-resultats-de-letude\/","title":{"rendered":"Anifrolumab Plus Standard Care r\u00e9duit les l\u00e9sions organiques chez les patients atteints de LED : r\u00e9sultats de l\u2019\u00e9tude"},"content":{"rendered":"<p>[et_pb_section fb_built=\u00a0\u00bb1&Prime; _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb-29px||||false|false\u00a0\u00bb da_disable_devices=\u00a0\u00bboff|off|off\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb da_is_popup=\u00a0\u00bboff\u00a0\u00bb da_exit_intent=\u00a0\u00bboff\u00a0\u00bb da_has_close=\u00a0\u00bbon\u00a0\u00bb da_alt_close=\u00a0\u00bboff\u00a0\u00bb da_dark_close=\u00a0\u00bboff\u00a0\u00bb da_not_modal=\u00a0\u00bbon\u00a0\u00bb da_is_singular=\u00a0\u00bboff\u00a0\u00bb da_with_loader=\u00a0\u00bboff\u00a0\u00bb da_has_shadow=\u00a0\u00bbon\u00a0\u00bb][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb-20px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_heading title=\u00a0\u00bbComment l\u2019anifrolumab aide \u00e0 r\u00e9duire les dommages aux organes du lupus\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb title_text_align=\u00a0\u00bbcenter\u00a0\u00bb title_font_size=\u00a0\u00bb24px\u00a0\u00bb custom_margin=\u00a0\u00bb|48px|||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px||0px|false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_heading][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb35px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p data-start=\"307\" data-end=\"573\" class=\"\">Le lupus \u00e9ryth\u00e9mateux diss\u00e9min\u00e9 (LED) est une maladie auto-immune chronique qui peut provoquer une inflammation g\u00e9n\u00e9ralis\u00e9e et des l\u00e9sions irr\u00e9versibles aux organes. Pour g\u00e9rer efficacement le LED, il faut contr\u00f4ler l\u2019activit\u00e9 de la maladie, pr\u00e9venir les pouss\u00e9es et minimiser l\u2019utilisation \u00e0 long terme de glucocortico\u00efdes. <\/p>\n<p data-start=\"575\" data-end=\"837\" class=\"\">Une \u00e9tude r\u00e9cente a compar\u00e9 les effets de <strong data-start=\"614\" data-end=\"657\">l\u2019anifrolumab associ\u00e9 au traitement standard (SOC)<\/strong> \u00e0 ceux de contr\u00f4les externes r\u00e9els recevant uniquement du SOC. Les r\u00e9sultats sugg\u00e8rent que l\u2019anifrolumab peut aider \u00e0 <strong data-start=\"758\" data-end=\"794\">r\u00e9duire l\u2019accumulation de l\u00e9sions organiques<\/strong> chez les patients atteints de LED mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re. <\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb28px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_heading title=\u00a0\u00bbPrincipales constatations\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb title_level=\u00a0\u00bbh4&Prime; title_font=\u00a0\u00bb||||||||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_heading][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb15px||||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb|0px|2px|||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<ul>\n<li data-start=\"862\" data-end=\"1010\" class=\"\">\n<p data-start=\"864\" data-end=\"1010\" class=\"\">Les patients qui ont re\u00e7u <strong data-start=\"886\" data-end=\"910\">de l\u2019anifrolumab plus un SOC<\/strong> ont accumul\u00e9 beaucoup <strong data-start=\"937\" data-end=\"958\">moins de l\u00e9sions organiques<\/strong> sur 208 semaines que ceux qui ont re\u00e7u du SOC seul.<\/p>\n<\/li>\n<li data-start=\"1011\" data-end=\"1141\" class=\"\">\n<p data-start=\"1013\" data-end=\"1141\" class=\"\"><strong data-start=\"1013\" data-end=\"1045\">L\u2019utilisation \u00e0 long terme de glucocortico\u00efdes<\/strong> est associ\u00e9e \u00e0 une augmentation des l\u00e9sions organiques, d\u2019o\u00f9 l\u2019importance d\u2019approches de traitement alternatives.<\/p>\n<\/li>\n<li data-start=\"1142\" data-end=\"1266\" class=\"\">\n<p data-start=\"1144\" data-end=\"1266\" class=\"\">Ces r\u00e9sultats sugg\u00e8rent que l\u2019ajout d\u2019anifrolumab au SOC pourrait \u00eatre une <strong data-start=\"1223\" data-end=\"1255\">strat\u00e9gie de traitement \u00e0 long terme<\/strong> plus efficace pour le LED.<\/p>\n<\/li>\n<\/ul>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb background_image=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2024\/05\/Rectangle-1674.png\u00a0\u00bb custom_margin=\u00a0\u00bb20px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.25.0&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_heading title=\u00a0\u00bbImplications pour le traitement du LED\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb title_level=\u00a0\u00bbh4&Prime; title_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb custom_margin=\u00a0\u00bb30px||||false|false\u00a0\u00bb hover_enabled=\u00a0\u00bb0&Prime; global_colors_info=\u00a0\u00bb{}\u00a0\u00bb sticky_enabled=\u00a0\u00bb0&Prime;][\/et_pb_heading][et_pb_text _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb custom_margin=\u00a0\u00bb-16px||30px||false|false\u00a0\u00bb custom_padding=\u00a0\u00bb6px||0px|||\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb]<\/p>\n<p><span style=\"color: #ffffff;\">La r\u00e9duction des l\u00e9sions organiques dans le LED est cruciale pour am\u00e9liorer <strong data-start=\"1349\" data-end=\"1427\">la qualit\u00e9 de vie, r\u00e9duire les co\u00fbts des soins de sant\u00e9 et minimiser les risques de mortalit\u00e9<\/strong>. Cette \u00e9tude fournit des preuves suppl\u00e9mentaires que l\u2019anifrolumab peut \u00eatre une option pr\u00e9cieuse pour les patients ayant besoin d\u2019un meilleur contr\u00f4le de la maladie. <\/span><\/p>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_column type=\u00a0\u00bb4_4&Prime; _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][et_pb_button button_url=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2025\/03\/Toronto-LASER-Study.pdf\u00a0\u00bb url_new_window=\u00a0\u00bbon\u00a0\u00bb button_text=\u00a0\u00bbVoir l\u2019\u00e9tude compl\u00e8te\u00a0\u00bb button_alignment=\u00a0\u00bbcenter\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb button_text_size=\u00a0\u00bb18px\u00a0\u00bb button_text_color=\u00a0\u00bb#FFFFFF\u00a0\u00bb button_bg_color=\u00a0\u00bb#6B198A\u00a0\u00bb custom_margin=\u00a0\u00bb38px||||false|false\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_button][et_pb_image src=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2025\/03\/Toronto-LASER-Study-pdf.jpg\u00a0\u00bb title_text=\u00a0\u00bb\u00c9tude LASER \u00e0 Toronto\u00a0\u00bb url=\u00a0\u00bbhttps:\/\/www.lupuscanada.org\/wp-content\/uploads\/2025\/03\/Toronto-LASER-Study.pdf\u00a0\u00bb url_new_window=\u00a0\u00bbon\u00a0\u00bb _builder_version=\u00a0\u00bb4.27.4&Prime; _module_preset=\u00a0\u00bbdefault\u00a0\u00bb global_colors_info=\u00a0\u00bb{}\u00a0\u00bb][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Cette \u00e9tude d\u00e9montre que l\u2019ajout d\u2019anifrolumab aux soins standard r\u00e9duit les l\u00e9sions organiques chez les patients atteints de lupus \u00e9ryth\u00e9mateux diss\u00e9min\u00e9 (LED) mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re. L\u2019\u00e9tude a compar\u00e9 les effets \u00e0 long terme de l\u2019anifrolumab et des soins standard \u00e0 des contr\u00f4les externes du monde r\u00e9el et a montr\u00e9 des avantages significatifs dans la pr\u00e9vention de l\u2019accumulation de l\u00e9sions organiques. <\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[92],"tags":[338,328,167,340,330,339,165,166,337,341],"topic":[113,115],"audience":[123,125,124],"class_list":["post-9876","post","type-post","status-publish","format-standard","hentry","category-article-fr","tag-lanifrolumab","tag-traitement-a-lanifrolumab","tag-recherche-canadienne","tag-gestion-des-maladies-chroniques","tag-traitement-du-lupus","tag-lesions-organiques-dans-le-led","tag-recherche","tag-sle-fr","tag-traitement-du-led","tag-lupus-erythemateux-dissemine","topic-nouvelles-et-evenements","topic-recherche-et-essais-cliniques","audience-j-ai-le-lupus","audience-professionnel-de-la-sante","audience-une-personne-a-qui-je-tiens-a-le-lupus"],"acf":[],"_links":{"self":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/9876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/comments?post=9876"}],"version-history":[{"count":0,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/posts\/9876\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/media?parent=9876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/categories?post=9876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/tags?post=9876"},{"taxonomy":"topic","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/topic?post=9876"},{"taxonomy":"audience","embeddable":true,"href":"https:\/\/www.lupuscanada.org\/fr\/wp-json\/wp\/v2\/audience?post=9876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}